Vistagen presents exploratory PH80 data at Menopause Society meeting

Vistagen (VTGN) presented exploratory data at The Menopause Society 2025 annual meeting in Orlando, Florida. These findings demonstrate PH80’s potential as a rapidly-acting pherine product candidate for treating vasomotor symptoms due to menopause. The research presented by Vistagen supports PH80’s ability to reduce autonomic nervous system activity after intranasal administration and noted that PH80 was not absorbed into the blood in humans. Nonclinical studies demonstrated that PH80 had no binding activity on steroid hormones or neurotransmitter receptors in vitro and had no effects on reproductive organs in laboratory mice and rats. Additional findings from the poster presentations by Vistagen at The Menopause Society meeting reveal insights into PH80, including: intranasally-administered PH80 nasal spray does not bind to steroid hormone receptors, nor does it bind to neurotransmitter receptors, including receptors linked to abuse liability potential. PH80 dose-dependently depolarizes the electrogram of nasal receptors in the nasal chemosensory epithelium. PH80 was not detected systemically in the blood of human volunteers. PH80 induces rapid-onset effects on physiologic markers of autonomic activity after intranasal administration. These previously unreported PH80 exploratory studies were sponsored by Pherin Pharmaceuticals, now a wholly owned subsidiary of Vistagen, between 1995 and 2000. Vistagen gained access to the results of the studies in connection with its acquisition of Pherin in 2023.